Merrimack Pharmaceuticals, Inc. (MACK) Social Stream

Featured Post From StockTwits About MACK

$MACK On July 29, 2021, as part of its H1 2021 Results Presentation, Ipsen
provided to the public an update on the RESILIENT trial of ONIVYDE as a
second line treatment for Small Cell Lung Cancer, indicating that
clinical data from this trial as well as a possible regulatory filing are
anticipated in 2022. Ipsen also provided an update on the NAPOLI 3 trial
of ONIVYDE as a first line treatment for pancreatic cancer. Enrollment is
continuing in this trial and Ipsen indicated that clinical data as well
as a possible regulatory filing are expected in 2023